Placebo Cohorts in Phase-3 MS Treatment Trials - Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Stellmann, Jan Patrick ^a   Neuhaus, Anneke ^b   Herich, Lena ^a   Schippling, Sven ^d   Roeckel, Matthias ^c   Daumer, Martin ^b   Martin, Roland ^d   Heesen, Christoph ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Sylvia Lawry Centre for Multiple Sclerosis Research   (Germany)

^c TEVA Pharma GmbH   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG; PLACEBO; RECOMBINANT GAMMA INTERFERON;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTIPLE SCLEROSIS; PATIENT ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREDICTIVE VALUE; RECURRENCE RISK; RISK REDUCTION; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; FEMALE; HUMANS; MALE; MODELS, STATISTICAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; POISSON DISTRIBUTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REGRESSION ANALYSIS; RESEARCH DESIGN; TIME FACTORS;

SYLVIA;

EID: 84870553278     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050347     Document Type: Article

References (34)

1. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New England Journal of Medicine: 387-401.
2. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. The New England journal of medicine 362: 416-426 doi:10.1056/NEJMoa0902533.
3. Jacobs LD, Cookfair DL, Rudick R a, Herndon RM, Richert JR, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Annals of neurology 39: 285-294 doi:10.1002/ana.410390304.
4. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352: 1498-1504 doi:10.1016/S0140-6736(98)03334-0.
5. Held U, Heigenhauser L, Shang C, Kappos L, Polman C, (2005) Predictors of relapse rate in MS clinical trials. Neurology 65: 1769-1773 doi:10.1212/01.wnl.0000187122.71735.1f.
6. Barkhof F, Held U, Simon JH, Daumer M, Fazekas F, et al. (2005) Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. Neurology 65: 1447-1454 doi:10.1212/01.wnl.0000183149.87975.32.
7. Daumer M, Neuhaus a, Morrissey S, Hintzen R, Ebers GC, (2009) MRI as an outcome in multiple sclerosis clinical trials. Neurology 72: 705-711 doi:10.1212/01.wnl.0000336916.38629.43.
8. Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, et al. (2010) Assessing changes in relapse rates in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). doi:10.1177/1352458510379246.
9. Lambert PC, Sutton J, Abrams KR, Jones DR, (2002) A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. Journal of clinical epidemiology 55: 86-94.
10. Higgins J, Green S, editors (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available. The Cochrane Collaboration. p.
11. Thompson SG, Sharp SJ, (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Statistics in medicine 18: 2693-2708.
12. McDonald WI, Compston a, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of neurology 50: 121-127.
13. Polman CH, Reingold SC, Edan G, Filippi M, Hartung H-peter, et al. (2005) Diagnostic Criteria for Multiple Sclerosis/: 2005 Revisions to the " McDonald Criteria. ". Annals of Neurology 11: 840-846 doi:10.1002/ana.206703.
14. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the "McDonald criteria." Annals of Neurology: n/a-n/a. doi:10.1002/ana.22366.
15. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 6: e1000097 doi:10.1371/journal.pmed.1000097.
16. Gelman A, Hill J (2009) Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge: Cambridge University Press. p.
17. Fahrmeir L, Tutz G (2001) Multivariate statistical modelling based on generalized linear models. 2nd ed. New York: Springer. p.
18. Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. Journal of 36.
19. Houwelingen HCV, Arends LR, Stijnen T, (2002) TUTORIAL IN BIOSTATISTICS Advanced methods in meta-analysis/: multivariate approach and meta-regression. Statistics in Medicine 624: 589-624 doi:10.1002/sim.1040.
20. R Development Core Team (2010) R: A language and environment for statistical computing.
21. Harrell Jr FE (2010) Hmisc: Harrell Miscellaneous. R package version 3.8-3.
22. Polman CH, O Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of Medicine 354: 899.
23. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, et al. (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50: 398-402.
24. IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. Neurology: 655-661.
25. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45: 1268-1276.
26. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349: 589-593.
27. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, et al. (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. The New England journal of medicine 366: 1000-1009 doi:10.1056/NEJMoa1104318.
28. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, et al. (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. The New England journal of medicine 365: 1293-1303 doi:10.1056/NEJMoa1014656.
29. Gold R, Kappos L, Bar-Or A, Arnold D, Giovannoni G, et al. (2011) Clinical efficacy of BG-12, an oral therapy, in relapsing-remitting multiple sclerosis: data from the phase 3 DEFINE trial. In: ECTRIMS. Amsterdam.
30. Selmaj K, Gold R, Kappos L, Dl A, Giovannoni G, et al. (2011) P994 Safety and Tolerability of BG-12 in the Phase 3 DEFINE Trial in Patients with Relapsing-Remitting Multiple Sclerosis. Multiple Sclerosis: 994.
31. Sormani MP, Tintorè M, Rovaris M, Rovira A, Vidal X, et al. (2008) Will Rogers phenomenon in multiple sclerosis. Annals of neurology 64: 428-433 doi:10.1002/ana.21464.
32. Okuda DT, Mowry EM, Beheshtian a, Waubant E, Baranzini SE, et al. (2008) Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome. Neurology 72: 800-805 doi:10.1212/01.wnl.0000335764.14513.1a.
33. Nicholas R, Straube S, Schmidli H, Schneider S, Friede T (2011) Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design. Multiple sclerosis (Houndmills, Basingstoke, England). doi:10.1177/1352458511406309.
34. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. The New England journal of medicine 362: 416-426 doi:10.1056/NEJMoa0902533.